For investors seeking momentum, Virtus Biotech Clinical Trials ETF BBC is probably on the radar now. The fund just hit a 52-week high and jumped 213.9% from its 52-week low price of $14.16 per share.
But are there more gains in store for this ETF? Let’s take a quick look at the fund and its near-term outlook to get a better sense of where it might head.
The fund provides exposure to select clinical trials-stage biotechnology companies. The product charges 79 basis points (bps) in annual fees (See: All Health Care ETFs).
The BBC ETF recently surged to a 52-week high, primarily driven by a resurgence in “risk-on” sentiment within the biotech sector. This momentum was fueled by a string of positive clinical trial outcomes from core holdings, alongside a significant uptick in M&A activity as Big Pharma seeks to acquire innovative pipelines.
Stabilizing interest rates provided a crucial tailwind for high-growth, pre-revenue companies. Coupled with recent breakthroughs in AI-driven drug discovery, these factors are likely to have created the perfect environment for the fund’s recent peak.
BBC may continue its strong performance in the near term, with a positive weighted alpha of 170.45 (as per Barchart.com), which suggests a further rally.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Virtus Biotech Clinical Trials ETF (BBC): ETF Research Reports
This article originally published on Zacks Investment Research (zacks.com).
Leave a comment